FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * CASCADE INVESTMENT, L.L.C. 2. Date of Event Requiring Statement (MM/DD/YYYY)
9/16/2021 

3. Issuer Name and Ticker or Trading Symbol Ginkgo Bioworks Holdings, Inc. [DNA]
(Last)       (First)       (Middle)
2365 CARILLON POINT
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)
KIRKLAND, WA 98033      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Class A Common Stock  151865481 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Includes 15,949,483 earn-out shares that will vest in four substantially equal installments if the issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00.

Remarks:
Exhibit List: Exhibit 24.1 - Power of Attorney (Cascade Investment, L.L.C.); Exhibit 24.2 - Power of Attorney (William H. Gates III)

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CASCADE INVESTMENT, L.L.C.
2365 CARILLON POINT
KIRKLAND, WA 98033

X

GATES WILLIAM H III
2365 CARILLON POINT
KIRKLAND, WA 98033

X


Signatures
Cascade Investment, L.L.C. By: /s/ Alan Heuberger, Attorney-in-fact for Michael Larson, Business Manager 9/24/2021
**Signature of Reporting Person Date
William H. Gates III By: /s/ Alan Heuberger, Attorney-in-fact 9/24/2021
**Signature of Reporting Person Date
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Ginkgo Bioworks Charts.
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Ginkgo Bioworks Charts.